Verici Dx plc (VRCDF)

Market Cap	3.72M
Revenue (ttm)	3.34M
Net Income (ttm)	-5.87M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	707
Average Volume	35
Open	0.1200
Previous Close	0.0300
Day's Range	0.0300 - 0.1200
52-Week Range	0.0300 - 0.1200
Beta	1.46
RSI	25.74
Earnings Date	Jul 15, 2025

About Verici Dx

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 14
• Stock Exchange: OTCMKTS
• Ticker Symbol: VRCDF

Financial Performance

In 2024, Verici Dx's revenue was $3.34 million, an increase of 229.62% compared to the previous year's $1.01 million. Losses were -$5.87 million, -32.75% less than in 2023.